RYIS Viracta Therapeutics Inc

Sunesis Pharmaceuticals Announces Presentation of SNS-510 Preclinical Data at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Sunesis Pharmaceuticals Announces Presentation of SNS-510 Preclinical Data at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
EN
12/10/2020

Underlying

RYISViracta Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Viracta Therapeutics Inc

 PRESS RELEASE
Free
RYIS Viracta Therape...

Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive M...

Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement Merger to create Nasdaq-listed company focused on developing Viracta’s precision oncology pipeline targeting virus-associated malignancies Registration trial for Viracta’s lead program in Epstein-Barr virus (EBV)-positive lymphomas expected to begin in the first half of 2021 Leading institutional investors committed a total of $105 million in private financings with Viracta Combined company expected to have approximately $120 million cash balance following the close of the merger Companies to ...

November 30, 2020 1 EN
 PRESS RELEASE
Free
RYIS Viracta Therape...

Sunesis Pharmaceuticals Reports Third Quarter 2020 Financial Results a...

Sunesis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the third quarter ended September 30, 2020. Loss from operations for the three months ended September 30, 2020 was $4.5 million. As of September 30, 2020, cash and cash equivalents totaled $26.0 million. During the third quarter, the Company raised approximately $12.6 million in net proceeds fr...

November 16, 2020 1 EN
 PRESS RELEASE
Free
RYIS Viracta Therape...

Sunesis Pharmaceuticals to Host Conference Call on November 16th to Di...

Sunesis Pharmaceuticals to Host Conference Call on November 16th to Discuss Third Quarter 2020 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Monday, November 16th, 2020 at 4:30pm Eastern Time to discuss corporate updates and financial results for the third quarter ended September 30, 2020. The call can be accessed by dialing (844) 296-7720 (U.S. and Canada) or (574) 990-1148 (international) and entering passcode 1776248. To access t...

November 9, 2020 1 EN
 PRESS RELEASE
Free
RYIS Viracta Therape...

Sunesis Pharmaceuticals Announces Presentation of SNS-510 Preclinical ...

Sunesis Pharmaceuticals Announces Presentation of SNS-510 Preclinical Data at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

October 12, 2020 1 EN
 PRESS RELEASE
Free
RYIS Viracta Therape...

Sunesis Pharmaceuticals Announces Participation at Upcoming Investor C...

Sunesis Pharmaceuticals Announces Participation at Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the Company will present at two upcoming virtual investor conferences. Wells Fargo 2020 Virtual Healthcare ConferenceDate: Thursday, September 10Time: 2:00 PM Eastern Time Oppenheimer Fall Healthcare Life Sciences & MedTech SummitDate: Tuesday, September 21Time: 4:10 PM Eastern Time Live webcasts of the events will be available on the Sunesis website at . A replay of each will b...

September 3, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch